The Food and Drug Administration (FDA) has issued a list of supplemental duodenoscope reprocessing measures to further reduce the risk of infection and increase the safety of these medical devices.
Par Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved Ethacrynate Sodium for Injection, the first generic version of Aton Pharma's Sodium Edecrin.
The Food and Drug Administration (FDA) confirmed that a case of definite progressive multifocal leukoencephalopathy (PML) and probable PML have been reported in patients taking Gilenya (fingolimod; Novartis) for multiple sclerosis.
The Phase 3 study of Kynamro (mipomersen sodium; Isis) met its primary endpoint in patients with severe heterozygous familial hypercholesterolemia (severe HeFH).
Clinicians should carefully consider the risks and benefits of triple therapy, as new research reports that in older patients with acute myocardial infarction (MI) and atrial fibrillation (AF), triple therapy did not reduce the risk of major cardiovascular events but was associated with a greater risk of bleeding.